Brinsulrapi MC 40 IU/ml

Diabetes mellitus (type 1) in children and adults, diabetes mellitus (type 2) (in the case of resistance to oral hypoglycemic agents, including partial during combination therapy, against the background of intercurrent diseases, during pregnancy).

P/c, the dose is determined individually. The solution must be injected immediately after the set into the syringe. A daily dose exceeding 0.6 U / kg should be administered in the form of two or more injections in different areas of the body.

Hypersensitivity, hypoglycemia.

Hypoglycemia (pallor of the skin, increased sweating, palpitation, tremor), allergic reactions (skin rash, rarely-angioedema, extremely rarely-anaphylactic shock), hyperemia, itching, lipodystrophy (with prolonged use) at the injection site, transient refractive errors (usually at the beginning of therapy).

Symptoms: a sharp increase in sweating, palpitations, tremors, hunger, agitation, paresthesia in the mouth, pallor, headache, in severe cases — hypoglycemic coma.

Treatment: ingestion of sugar or foods rich in carbohydrates, in severe cases-the introduction of glucose (20-40 ml of 40% solution / in) and glucagon (1 mg/m).

• Insulins

MAO inhibitors, non-selective beta-blockers, sulfonamides, anabolic steroids, tetracyclines, clofibrate, cyclophosphamide, fenfluramine, drugs containing ethanol, enhance the hypoglycemic effect, oral contraceptives, glucocorticoids, thyroid hormones, thiazide diuretics, heparin, lithium preparations, tricyclic antidepressants-weaken. Reserpine and salicylates can both weaken and enhance the hypoglycemic effect.

In a place protected from light, at a temperature of 2-8 °C. Do not allow freezing.

Keep out of reach of children.

Do not use after the expiration date indicated on the package.

1 ml of the solution for injection contains pig highly purified monocomponent insulin 40 units, as well as 3 mg of metacresol as a preservative, in glass bottles of 10 ml, in a cardboard pack of 1 bottle.

Patients receiving more than 100 units/day of Brinsulrapi MK, when changing the drug, it is advisable to be hospitalized.

The transition from one type of insulin to another should be carried out under the control of blood glucose levels.

With the initial appointment, a change in the type of insulin or the occurrence of stressful situations during treatment, it is possible to reduce the ability to drive vehicles and mechanisms, to other potentially dangerous activities that require increased attention and speed of reaction.

With changes in the nature and diet, significant physical exertion, infectious diseases, surgical interventions, pregnancy, thyroid dysfunction, Addison's disease, hypopituitarism, renal failure, and in patients over 65 years of age, it is necessary to adjust the dose.

Insulin lowers the tolerance for alcohol.

A10AB Short-acting insulins and their analogues for injection

• E14 Diabetes mellitus, unspecified